Transfusion management of abdominal delivery in pregnant women at high risk of bleeding with hemostasis control

Objective of the study. Optimization of transfusion support of abdominal delivery in pregnant women at risk of obstetric haemorrhage using monitored management of haemostasis disorders.

Study materials. The study group consisted of 24 women of 23-47 years old with abnormal placental invasion (API) and bleeding during caesarean section at a gestational age of 32-36 weeks. Group 1 consisted of 14 patients, who were injected with tranexamic acid as part of combined therapy; Group 2 consisted of 10 women, who were injected with aminomethylbenzoic acid as part of combined therapy.

Results. All patients received instrumental autoerythrocyte reinfusion. Three patients of Group 1 (21.4%) with refractory bleeding received recombinant coagulation factor VIIa (Coagil, Russia) at a dose of 60 pg/kg body weight (average dose 6.6 ± 1.4 mg), a

decrease in bleeding was observed, the operative treatment was completed in the form of metroplasty. In the early stages of bleeding, eight patients were injected with a prothrombin complex concentrate of 600-1,200 IU before administration of fresh-frozen plasma (FFP), which allowed to reduce the volume of donor FFP in these patients. The study of hemostasis showed a very high inverse relationship between extent of blood loss and fibrinogen level in the groups of patients.

Conclusion. The use of factor VIIa in refractory major obstetric haemorrhage (MOH) in patients with API allows to reduce the blood loss, perform metroplasty, and preserve the woman’s fertility. Patient blood management (PCM) in pregnant women with API makes it possible to conduct organ-preserving treatment in 91.7% of women.

1. Say L., Chou D., Gemmill A., Tungalp O., Moller A.-B., Daniels J. et al. Global causes of maternal death: a WHO systematic analysis. Lancet Glob Health. 2014;2(6):323-333. doi: 10.1016/S2214-109X(14)70227-X.

2. Meybohm P., Froessler B., Goodnough L.T., Klein A.A., Munoz M., Murphy M.F. et al. Simplified International recommendations for the implementation of patient blood management (SIR4PBM). Perioper Med. 2017;6:5. doi: 10.1186/s13741-017-0061-8.

3. Silver R.M. Abnormal Placentation: Placenta previa, vasa previa and placenta accreta. Obstet Gynecol. 2015;126(3):654-668. doi: 10.1097/AOG.0000000000001005.

4. Cunningham K.M., Anwar A., Lindow S. The recurrence risk of placenta accreta following uterine conserving management. J Neonatal Perinatal Med. 2015;8(4):293-296. doi: 10.3233/NPM-15915028.

5. Radnia N., Manouchehrian N., Shayan A., Shirmohamadi N., Eskandarloo T., Otogara M. Frequency and causes of emergency hysterectomy along with vaginal delivery and caesarean section in Hamadan, Iran. Electron Physician. 2017;9(6):4643-4647. doi: 10.19082/4643.

6. Baldwin H.J., Patterson J.A., Nippita T.A., Torvaldsen S., Ibiebele I., Simpson J.M., Ford J.B. Maternal and neonatal outcomes following abnormally invasive placenta: a population-based record linkage study. Acta Obstet Gynecol Scand. 2017;96(11):1373-1381 doi: 10.1111/aogs.13201.

7. Brookfield K.F., Goodnough L.T., Lyell DJ., Butwick AJ. Perioperative and transfusion outcomes in women undergoing cesarean hysterectomy for abnormal placentation. Transfusion. 2014;54(6):1530-1536. doi: 10.1111/trf.12483.

8. Mhyre J.M., Shilkrut A., Kuklina E.V., Callaghan W.M., Creanga A., Kaminsky S., Bateman B. Massive blood transfusion during hospitalization for delivery in New York State, 1998-2007. Obstet Gynecol. 2013;122(6):1288-1294. doi: 10.1097/AOG.0000000000000021.

9. EshkoLi T., Weintraub R., Sergienko R., Sheiner Y. Placenta accreta: risk factors, perinatal outcomes, and consequences for subsequent births. Am J Obstet Gynecol. 2013;208(3):219.e1-7. doi: 10.1016/j.ajog.2012.12.037.

10. Fitzpatrick K.E., Sellers S., Spark P., Kurinczuk JJ., BrockLehurst P., Knight M. Incidence and risk factors for placenta accreta/increta/percreta in the UK: a national case-control study. PLoS One. 2012;7(12):e52893. doi: 10.1371/journal.pone.0052893.

11. Rosenberg T., Pariente G., Sergienko R., Wiznitzer A., Sheiner E. Critical analysis of risk factors and outcome of placenta previa. Arch Gynecol Obstet. 2011;284(1):47-51. doi: 10.1007/s00404-010-1598-7.

12. Hung T.-H., Hsieh C.-C., Hsu J.-J., Lo L-M., Chiu T.-H., Hsieh T.-T. Risk factors for placental abruption in an Asian population. Reprod Sci. 2007;14(1):59-65. doi: 10.1177/1933719106298363.

13. Bunch K., Roberts N., Knight M., Nair M. Systematic review to investigate the safety of induction and augmentation of labour among pregnant women with iron-deficiency anaemia. BMJ Open. 2018;8(12):e021793. doi: 10.1136/bmjopen-2018-021793.

14. Clevenger B., Richards T. Pre-operative anaemia. Anaesthesia. 2015;70(S1):20-8, e6-8. doi: 10.1111/anae.12918.

15. Fowler AJ., Ahmad T., Phull M.K., Allard S., Gillies M.A., Pearse R.M. Metaanalysis of the association between preoperative anaemia and mortality after surgery. Br J Surg. 2015;102(11):1314-1324. doi: 10.1002/bjs.9861.

16. Zabelina T.M., Vasilchenko O.N., Shmakov R.G., Pirogova M.M., Karimova G.N., Chuprynin V.D. et al. The effectiveness of complex compression hemostasis in treating different grades of the placenta accreta spectrum disorders. Akusherstvo i ginekologiya = Obstetrics and Gynegology. 2020;(6):30-36. (In Russ.) doi: 10.18565/aig.2020.6.30-36.

17. Staikou C., Paraskeva A., Karmaniolou I., Mani A., Chondrogiannis K. Current practice in obstetric anesthesia: a 2012 European survey. Minev Anestesiol. 2014;80(3):347-354. Available at: https://pubmed.ncbi.nlm.nih.gov/24193179.

18. Eller A.G., Porter T.F., Soisson P.M., Silver R.M. Optimal management strategies for placenta accreta. BJOG. 2009;116(5):648-654. doi: 10.1111/j.1471-0528.2008.02037.x.

19. Markley J.C., Farber M.K., Perlman N.C., Carusi D.A. Neuraxial anesthesia during cesarean delivery for placenta previa with suspected morbidly adherent placenta: a retrospective analysis. Anesth Analg. 2018;127(4):930-938. doi: 10.1213/ANE.0000000000003314.

20. Sultan P., Hilton G., Butwick A., Carvalho B. Continuous spinal anesthesia for Cesarean hysterectomy and massive hemorrhage in a parturient with placenta increta. Can J Anaesth. 2012;59(5):473-477. doi: 10.1007/s12630-012-9681-0.

21. Marcellin L., Delorme P., Bonnet M.P., Grange G., Kayem G., Tsatsaris V., Goffinet F. Placenta percreta is associated with more frequent severe maternal morbidity than placenta accreta. Am J Obstet Gynecol. 2018;219(2):193.e1-193.e9. doi: 10.1016/j.ajog.2018.04.049.

22. Kozek-Langenecker S.A., Ahmed A.B., Afshari A., Albaladejo P., Aldecoa C., Barauskas G. et al. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology: First update 2016. Eur JAnaesthesiol. 2017;34(6):332-395. doi: 10.1097/EJA.0000000000000630.

23. Khan K., Moore P., Wilson M., Allard S., Wrench I., Roberts T. et al. A randomised controlled trial and economic evaluation of intraoperative cell salvage during caesarean section in women at risk of haemorrhage: the SALVO (cell SALVage in Obstetrics) trial. Health Technol Assess. 2018;22(2):1-88. doi: 10.3310/hta22020.

24. Serov V.N., Sokolova Yu. Yu., Fedorova T.A., Fomin M.D., Sokolov V.A., Rogachevsky O.V. Infusion-transfusion therapy of blood loss in obstetric care. Akusherstvo i ginekologiya = Obstetrics and Gynecology. 2005;(6):14-17. (In Russ.) Available at: https//elibrary.ru/item.asp?id=9141153.

25. Mavrides E., Allard S., Chandraharan E., Collins P., Green L., Hunt BJ., Riris S., Thomson AJ. on behalfof the Royal College of Obstetricians and Gynaecologists. Prevention and manag ement of postpartum haemorrhage. BJOG. 2016;124:e106-e149. doi: 10.1111/1471-0528.14178.

26. Kudlay D.A. Development and use of Russian recombinant blood coagulation factor VII, VIII, IX drugs in children with hemophilia A and B. Pediatriya = Pediatria. 2019;98(1):9-17. (In Russ.) Available at: https//pedi-atriajournal.ru/archive?show=368§ion=5421.

27. Galstyan G.M., Polevodova O.A., Terekhova I.V., Konyashina N.I., Polyanskaya T.Yu., Zorenko V.Yu., Kudlay D.A. The use of thromboelastogra-phy, thrombin generation test and clotting tests to evaluate the efficacy of hemostatic therapy with recombinant activated factor VII in hemophilia patients with inhibitor. Rossiyskiy zhurnal detskoy gematologii i onkologii = Russian Journal of Pediatric Hematology and Oncology. 2017;4(4):33-38. (In Russ.) doi: 10.17650/2311-1267-2017-4-4-33-38.

28. Rybka M.M., Samsonova N.N., Lobacheva G.V., Klimovich L.G., Kozar E.F., Rogalskaya E.A. Effectiveness and safety of coagil-vii - eptacog alfa (activated) in surgical correction of congenital heart diseases in newborns and infants. Tromboz, gemostaz i reologiya = Trombosis, Hemostasis and Reology. 2014;(1):9-14. (In Russ.) Available at: https//elibrary.ru/item.asp?id=21223972.

29. Magon N., Babu K.M. Recombinant Factor VIIa in Post-partum Hemorrhage: A New Weapon in Obstetrician's Armamentarium. N Am J Med Sci. 2012;4(4):157-162. doi: 10.4103/1947-2714.94938.

30. Lavigne-Lissalde G., Aya G., Mercier F., Roger-Christoph S., Chauleur C., Morau E. et al. Recombinant human FVIIa for reducing the need for invasive second-line therapies in severe refractory postpartum hemorrhage: a multicenter, randomized, open controlled trial. J Thromb Haemost. 2015;13(4):520-529. doi: 10.1111/jth.12844.

31. Kuznik B.I., Sturov V.G., Levshin N.Yu.; Kuznik B.I. (ed.) Hemorrhagic and thrombotic diseases and syndromes in children and adolescents: pathogenesis, clinical presentation, diagnosis, therapy, and prevention. Novosibirsk: Nauka; 2018. 524 p. (In Russ.) Available at: https://search.rsl.ru/ru/record/01009803605.

32. Momot A.P., Molchanova I.V., Tskhai V.B. Massive obstetric hemorrhage: from hysterectomy to drug therapy. Voprosy gematologii/onkologii i immu-nopatologii v pediatrii = Pediatric Hematology/Oncology and Immunopathology. 2012;11(2):32-37. (In Russ.) Available at: https://elibrary.ru/item.asp?id=17857989.

33. Kobayashi T., Nakabayashi M., Yoshioka A., Maeda M., Ikenoue T. Recombinant activated factor VII (rFVIIa/NovoSeven®) in the management of severe postpartum haemorrhage: initial report of a multicentre case series in Japan. Int J Hematol. 2012;95(1):57-63. doi: 10.1007/s12185-011-0974-9.

34. Colucci G., Helsing K., Demarmels Biasiutti F., Raio L., Schmid P., Tsakiris D.A. et al. Standardized management protocol in severe postpartum hemorrhage: a single-center study. Clin Appl Thromb Hemost. 2018;24(6):884-893. doi: 10.1177/1076029618758956.

35. Pacheco L.D., Saade G.R., Hankins G.D.V. Medical management of postpartum hemorrhage: an update. Semin Perinatol. 2019;43(1):22-26. doi: 10.1053/j.semperi.2018.11.005.

36. Schjoldager B.T., Mikkelsen E., Lykke M.R., Pr^st J., Hvas A.-M., Heslet L. et al. Topical application of recombinant activated factor VII during cesarean delivery for placenta previa. Am J Obstet Gynecol. 2017;216:1-5. doi: 10.1016/j.ajog.2017.02.024.

37. Younis M., Ray-Zack M., Haddad N.N., Choudhry A., Hernandez M.C., Wise K., Zielinski M.D. Prothrombin complex concentrate reversal of coagulopathy in emergency general surgery patients. World J Surg. 2018;42(8):2383-2391. doi: 10.1007/s00268-018-4520-2.

38. Tanaka K.A., Mazzeffi M., Durila M. Role of prothrombin complex concentrate in perioperative coagulation therapy. J Intensive Care. 2014;2(1):60. doi: 10.1186/s40560-014-0060-5.

39. Rourke C., Curry N., Khan S., Taylor R., Raza I., Davenport R. et al. Fibrinogen levels during trauma hemorrhage, response to replacement therapy, and association with patient outcomes. J Thromb Haemost. 2012;10(7):1342-1351. doi: 10.1111/j.1538-7836.2012.04752.x.

40. Cortet M., Deneux-Tharaux C., Dupont C., Colin C., Rudigoz R.-C., Bouvier-Colle M.-H., Huissoud C. Association between fibrinogen level and severity of postpartum haemorrhage: secondary analysis of a prospective trial. Br J Anaesth. 2012;108(6):984-989. doi: 10.1093/bja/aes096.

41. Sebghati M., Chandraharan E. An update on the risk factors for and management of obstetric haemorrhage. Womens Health (Lond). 2017;13(2):34-40. doi: 10.1177/1745505717716860.

42. Karlsson O., Jeppsson A., Hellgren M. Major obstetric haemorrhage: monitoring with thromboelastography, laboratory analyses or both? Int J Obstet Anesth. 2014;23(1):10-17. doi: 10.1016/j.ijoa.2013.07.003.

43. Shen L., Tabaie S., Ivascu N. Viscoelastic testing inside and beyond the operating room. J Thorac Dis. 2017;9(S4):299-308. doi: 10.21037/jtd.2017.03.85.

44. Ataullakhanov F.I., Balandina A.N., Vardanyan D.M., Verkholomova F.Yu., Vuymo T.A., Krylov A.Yu. et al.; Shulutko A.M. (ed.) Application of the throm-bodynamics test to assess the state of the hemostatic system. Moscow: I.M. Sechenov First Moscow State Medical University; 2015. 72 p. (In Russ.) Available at: https://elibrary.ru/item.asp?id=25582267.

45. Sinauridze E.I., Vuimo T.A., Tarandovskiy I.D., Ovsepyan R.A., Surov S.S., Korotina N.G. et al. Thrombodynamics, a new global coagulation test: Measurement of heparin efficiency. Talanta. 2018;180:282-291. doi: 10.1016/j.talanta.2017.12.055.

46. Panigrahi A.K., Yeaton-Massey А., Bakhtary S., Andrews J., Lyell DJ., Butwick AJ., Goodnough L.T. A Standardized Approach for Transfusion Medicine Support in Patients with Morbidly Adherent Placenta. Anesth Analg. 2017;125(2):603-608. doi: 10.1213/ANE.0000000000002050.

47. DeSimone R.A., Leung W.K., Schwartz J. Transfusion medicine in a multidisciplinary approach to morbidly adherent placenta: preparing for and preventing the worst. Transfus Med Rev. 2018;32(4):244-248. doi: 10.1016/j.tmrv.2018.05.007.

48. Thurn L., Wikman A., Lindqvist P Postpartum blood transfusion and hemorrhage as independent risk factors for venous thromboembolism. Thromb Res. 2018;165:54-60. doi: 10.1016/j.thromres.2018.03.002.

49. Collins P.W., Bell S.F., de Lloyd L., Collis R.E. Management of postpartum haemorrhage: from research into practice, a narrative review of the literature and the Cardiff experience. Int J Obstet Anesth. 2019;35:106-117. doi: 10.1016/j.ijoa.2018.08.008.